Reteplase

CHEMBL2107885 Phase 4 Approuvé Enzyme
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

Reteplase is a recombinant deletion mutant of tissue plasminogen activator (tPA) that binds fibrin in thrombi and catalyzes the conversion of plasminogen to plasmin, which lyses fibrin clots and restores blood flow in occluded vessels. It is approved for the treatment of acute myocardial infarction and is used for management of massive pulmonary embolism and acute ischemic stroke.

Aires thérapeutiques

Mécanisme d'action

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Reteplase is a recombinant deletion mutant of tissue plasminogen activator (tPA) that binds fibrin in thrombi and catalyzes the conversion of plasminogen to plasmin, which lyses fibrin clots and restores blood flow in occluded vessels. It is approved for the treatment of acute myocardial infarction and is used for management of massive pulmonary embolism and acute ischemic stroke.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Reteplase is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107885. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.